NCT02992743View on ClinicalTrials.gov

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 6, 2016

Primary Completion Date

November 1, 2021

Study Completion Date

March 22, 2022

Conditions
Neoplasms
Interventions
DRUG

letetresgene autoleucel (GSK3377794)

Letetresgene autoleucel (GSK3377794) as an IV infusion.

DRUG

Cyclophosphamide

Cyclophosphamide will be used as a lymphodepleting chemotherapy.

DRUG

Fludarabine

Fludarabine will be used as a lymphodepleting chemotherapy.

Trial Locations (6)

10065

GSK Investigational Site, New York

33612

GSK Investigational Site, Tampa

43210

GSK Investigational Site, Columbus

48109

GSK Investigational Site, Ann Arbor

63110

GSK Investigational Site, St Louis

77030

GSK Investigational Site, Houston

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY